Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECAPTURE: Ceftazidime-Avibactam vs Doripenem in cUTI
NCT01595438Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2012
- Primary completion
- Aug 2014
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of ceftazidime + avibactam in complicated urinary tract infection (cUTI) and acute pyelonephritis (2 arms), sponsored by Pfizer. Primary endpoints: Patient-reported Symptomatic Response at Day 5, Combined Patient-reported Symptomatic and Microbiological Response and 1 more. Started Oct 2012; status: completed.
02
Drugs
ceftazidime + avibactam
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on NCT01595438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01595438.